Rep. Greg Landsman Sells Pfizer Inc. (NYSE:PFE) Shares

Representative Greg Landsman (D-Ohio) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on November 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on October 15th. The trade occurred in the Representative’s “ROCKEFELLER CAPITAL MANAGEMENT (2)” account.

Representative Greg Landsman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Cheniere Energy (NYSE:LNG) on 10/15/2024.
• Sold $15,001 – $50,000 in shares of Phillips 66 (NYSE:PSX) on 10/15/2024.
• Sold $15,001 – $50,000 in shares of Diamondback Energy (NASDAQ:FANG) on 10/15/2024.
• Sold $1,001 – $15,000 in shares of NextEra Energy (NYSE:NEE) on 10/15/2024.
• Sold $1,001 – $15,000 in shares of Linde (NASDAQ:LIN) on 10/15/2024.
• Sold $1,001 – $15,000 in shares of Regeneron Pharmaceuticals (NASDAQ:REGN) on 10/15/2024.
• Sold $1,001 – $15,000 in shares of CrowdStrike (NASDAQ:CRWD) on 10/15/2024.
• Sold $15,001 – $50,000 in shares of Exxon Mobil (NYSE:XOM) on 10/15/2024.
• Sold $15,001 – $50,000 in shares of Amazon.com (NASDAQ:AMZN) on 10/15/2024.
• Purchased $1,001 – $15,000 in shares of NextEra Energy (NYSE:NEE) on 9/10/2024.

Pfizer Stock Down 4.7 %

Shares of Pfizer stock opened at $24.80 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The stock has a market capitalization of $140.54 billion, a price-to-earnings ratio of 33.51, a P/E/G ratio of 0.85 and a beta of 0.67. The company’s 50 day moving average price is $28.71 and its 200-day moving average price is $28.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter last year, the business earned ($0.17) earnings per share. The business’s revenue was up 31.2% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.77%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is 227.03%.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Frisch Financial Group Inc. raised its stake in Pfizer by 3.9% during the third quarter. Frisch Financial Group Inc. now owns 34,334 shares of the biopharmaceutical company’s stock valued at $994,000 after purchasing an additional 1,287 shares in the last quarter. Brophy Wealth Management LLC purchased a new stake in Pfizer during the third quarter valued at $945,000. Executive Wealth Management LLC purchased a new stake in Pfizer during the third quarter valued at $476,000. Nabity Jensen Investment Management Inc purchased a new stake in Pfizer during the third quarter valued at $347,000. Finally, Continuum Advisory LLC raised its stake in shares of Pfizer by 11.8% in the third quarter. Continuum Advisory LLC now owns 28,148 shares of the biopharmaceutical company’s stock valued at $815,000 after acquiring an additional 2,963 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PFE. UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Wells Fargo & Company lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, eight have given a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

About Representative Landsman

Greg Landsman (Democratic Party) is a member of the U.S. House, representing Ohio’s 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2025. Landsman is also a member of the Cincinnati City Council in Ohio. He assumed office on January 2, 2018. His current term ends on January 1, 2024. Landsman (Democratic Party) is running for re-election to the U.S. House to represent Ohio’s 1st Congressional District. He declared candidacy for the 2024 election. Greg Landsman was born in Cincinnati, Ohio, and lives in Mt. Washington, Ohio. Landsman earned a B.A. in economics and political science from Ohio University and an M.A. in theological studies, religion, and public policy from Harvard University in 2004. His career experience includes working as the executive director of The Strive Partnership with the KnowledgeWorks Foundation and the director of the Ohio Governor’s Office of Faith-Based and Community Initiatives.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.